We are live on ! Find out more

Medpace

MEDP

Market cap $17.1B

611.42 USD

-8.61

1.39%

At close Updated Aug 25, 11:34 AM EDT

1 day

-1.39%

5 days

1.9%

1 month

3.74%

3 months

42.49%

6 months

39.57%

Year to date

7.08%

1 year

30.98%

5 years

238.46%

10 years

2,108.09%

About: Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.

Employees: 6,500

Healthcare Diagnostics & Research

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 18.4%

Neutral 79.8%

Negative 1.8%

Zacks Investment Research

Why Is Medpace (MEDP) Up 1.1% Since Last Earnings Report?

Medpace (MEDP) reported earnings 30 days ago. What's next for the stock?

Why Is Medpace (MEDP) Up 1.1% Since Last Earnings Report?

Zacks Investment Research

Medpace (MEDP) is an Incredible Growth Stock: 3 Reasons Why

Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.

Medpace (MEDP) is an Incredible Growth Stock: 3 Reasons Why

Zacks Investment Research

CON or MEDP: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical Services sector have probably already heard of Concentra Group (CON) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?

CON or MEDP: Which Is the Better Value Stock Right Now?

Zacks Investment Research

Here's Why Medpace (MEDP) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Medpace (MEDP) is a Strong Growth Stock

Kuehn Law Encourages Investors of Medpace Holdings, Inc. to Contact Law Firm

NEW YORK, Aug. 10, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Medpace Holdings, Inc. (NASDAQ: MEDP) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Medpace Holdings misrepresented or failed to disclose material information concerning the Company's backlog cancellation rates, business conditions, and ability to maintain its projected 1.15 book-to-bill ratio.

Kuehn Law Encourages Investors of Medpace Holdings, Inc. to Contact Law Firm

Zacks Investment Research

Medpace (MEDP) Just Flashed Golden Cross Signal: Do You Buy?

Medpace Holdings, Inc. (MEDP) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MEDP's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.

Medpace (MEDP) Just Flashed Golden Cross Signal: Do You Buy?

Zacks Investment Research

Is MEDP Worth Buying as Growth Collides With a Premium Valuation?

Medpace pairs double-digit growth, record awards and a strong balance sheet with a rich valuation, raising the question of whether the premium already prices in its outlook.

Is MEDP Worth Buying as Growth Collides With a Premium Valuation?

Zacks Investment Research

Can MEDP's Record Q2 Bookings Build a Stronger Growth Path for 2027?

Medpace Holdings, Inc. MEDP regained commercial momentum in the second quarter of 2026 as record awards and a higher book-to-bill ratio reversed the weaker first-quarter trend.

Can MEDP's Record Q2 Bookings Build a Stronger Growth Path for 2027?

Zacks Investment Research

Why Medpace (MEDP) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Medpace (MEDP) is a Top Momentum Stock for the Long-Term

Zacks Investment Research

3 Reasons Why Growth Investors Shouldn't Overlook Medpace (MEDP)

Medpace (MEDP) could produce exceptional returns because of its solid growth attributes.

3 Reasons Why Growth Investors Shouldn't Overlook Medpace (MEDP)

See News Rankings

Price charts implemented using Lightweight Charts™